Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 14586547)

Published in World J Urol on October 29, 2003

Authors

Dirk Schultheiss1, Rafael Badalyan, Adrian Pilatz, Alexander I Gabouev, Norbert Schlote, Jörg Wefer, Reinhard von Wasielewski, Heike Mertsching, Michael Sohn, Christian G Stief, Udo Jonas

Author Affiliations

1: Department of Urology and Pediatric Urology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. schultheiss.dirk@mh-hannover.de

Articles cited by this

Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation (1999) 1.58

Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology (1999) 1.42

A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol (1996) 1.17

Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology (2002) 1.12

Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) (2003) 1.12

Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol (1985) (2001) 1.05

Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol (2000) 1.05

Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther (1996) 1.02

The effect of testosterone on androgen receptors and human penile growth. J Urol (1997) 1.01

Evidence for a potential role of estrogen in the penis: detection of estrogen receptor-alpha and -beta messenger ribonucleic acid and protein. Endocrinology (2002) 1.00

Expression of functional estrogen receptors in human fetal male external genitalia. J Clin Endocrinol Metab (2003) 0.96

Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod (1996) 0.92

The effects of testosterone on the cavernous tissue and erectile function. World J Urol (1997) 0.91

Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int (1999) 0.91

The autonomic nerve supply of male sex organs--an important target of circulating androgens. Behav Brain Res (1999) 0.89

Up-regulation of the levels of androgen receptor and its mRNA by androgens in smooth-muscle cells from rat penis. Mol Cell Endocrinol (1993) 0.87

Identification, partial characterization and age-related changes of a cytoplasmic androgen receptor in the rat penis. J Steroid Biochem (1980) 0.85

Androgen induction of DNA synthesis in the rat penis. Urology (1998) 0.84

Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology (2000) 0.81

Androgen-sensitive preganglionic neurons innervate the male rat pelvic ganglion. Neuroscience (1999) 0.80

Micropenis in hypogonadotropic hypogonadism: response of the penile androgen receptor to testosterone treatment. J Urol (1998) 0.79

Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav (1997) 0.79

Cavernous and systemic testosterone levels in different phases of human penile erection. Urology (2000) 0.78

The effects of castration on relaxation of rat corpus cavernosum smooth muscle in vitro. J Urol (1999) 0.77

Localization of androgen receptor in nitric oxide synthase- and vasoactive intestinal peptide-containing neurons of the major pelvic ganglion innervating the rat penis. J Neuroendocrinol (1997) 0.77

Age-dependent changes in androgen receptor immunoreactivity in motoneurons of the spinal nucleus of the bulbocavernosus of male rats. Neurosci Lett (1998) 0.76

Androgen binding activity in the spongy tissue of mammalian penis. J Urol (1990) 0.76

Comparison between plasma concentrations of testosterone, nitric oxide and endothelin 1-2 in penile and brachial venous blood: preliminary results in men with psychogenic impotence. Biomed Pharmacother (1998) 0.76

The association of ED (erectile dysfunction) with ED (endothelial dysfunction) in the International Journal of Impotence Research: The Journal of Sexual Medicine. Int J Impot Res (2003) 0.76

The effects of testosterone deficiency on male sexual function. Aging Male (2002) 0.75

Androgen receptor levels in the rat penis are controlled differently in distinctive cell types. Endocrinology (1991) 0.75

The Role of Andorgens in the Erectile Response: A 1999 Perspective. Mol Urol (1999) 0.75

Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction. Urology (2001) 0.75

Castration enhances NANC nerve-mediated relaxation in rabbit isolated corpus cavernosum. Acta Physiol Scand (1992) 0.75

Endocrine causes of impotence (nondiabetes). Urol Clin North Am (2003) 0.75

Testosterone receptors in corpora cavernosa of penis. Urology (1985) 0.75

Androgenic maintenance of the erectile response in the rat. Steroids (1999) 0.75

Articles by these authors

Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60

Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57

Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99

Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97

Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol (2012) 2.87

Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol (2008) 2.52

Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30

Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26

The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13

Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11

Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08

High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06

Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol (2006) 2.05

Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04

Functional neointima characterization of vascular prostheses in human. Ann Thorac Surg (2004) 2.01

Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01

First human transplantation of a bioengineered airway tissue. J Thorac Cardiovasc Surg (2004) 1.94

The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med (2010) 1.91

A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76

Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74

Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol (2002) 1.71

Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70

Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65

Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63

Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62

Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures. J Urol (2005) 1.61

Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61

Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61

Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology (2009) 1.59

Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57

18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54

Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol (2007) 1.53

High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51

Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol (2011) 1.51

Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. Eur Urol (2009) 1.51

Laparoscopy in German urology: changing acceptance among urologists. Eur Urol (2008) 1.51

The impact of deep and moderate body temperatures on end-organ function during hypothermic circulatory arrest. Eur J Cardiothorac Surg (2011) 1.51

Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50

Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology (2010) 1.49

The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49

Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol (2002) 1.48

Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46

Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology (2008) 1.46

Expression of guanylyl cyclase B in the human corpus cavernosum penis and the possible involvement of its ligand C-type natriuretic polypeptide in the induction of penile erection. J Urol (2003) 1.46

Postprostatectomy incontinence: all about diagnosis and management. Eur Urol (2008) 1.44

Hypothermic circulatory arrest with moderate, deep or profound hypothermic selective antegrade cerebral perfusion: which temperature provides best brain protection? Eur J Cardiothorac Surg (2006) 1.44

Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43

The complex structure of the smooth muscle layer of spermatic veins and its potential role in the development of varicocele testis. Eur Urol (2006) 1.43

Are antisperm antibodies really associated with proven chronic inflammatory and infectious diseases of the male reproductive tract? Eur Urol (2008) 1.40

Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol (2009) 1.40

Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology (2002) 1.38

Castrati singers--all for fame. J Sex Med (2012) 1.37

Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med (2010) 1.35

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation (2002) 1.27

Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology (2009) 1.25

Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem (2007) 1.25

Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol (2009) 1.22

Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int (2009) 1.21

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res (2007) 1.20

Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol (2003) 1.19

Engineered liver-like tissue on a capillarized matrix for applied research. Tissue Eng (2007) 1.19

Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. J Surg Res (2007) 1.18

Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol (2005) 1.17

Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat (2006) 1.16

Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat (2006) 1.15

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol (2009) 1.15

Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol (2010) 1.14

Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol (2009) 1.14

Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences. Urology (2008) 1.12

Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol (2007) 1.12

Monitoring the coupling of the lithotripter therapy head with skin during routine shock wave lithotripsy with a surveillance camera. J Urol (2011) 1.11

Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation (2006) 1.09

Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09

Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer (2009) 1.08

Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07

Ultrasound measurement of detrusor wall thickness in healthy adults. Neurourol Urodyn (2006) 1.07

IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch (2003) 1.06

Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06

RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer (2007) 1.06

Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol (2012) 1.05

Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol (2006) 1.05

Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med (2012) 1.04

In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res (2006) 1.04

Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol (2006) 1.03

Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol (2012) 1.02

Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol (2010) 1.02

Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol (2009) 1.01

Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01

Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. Antimicrob Agents Chemother (2013) 1.01

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00

Urosepsis--from the view of the urologist. Int J Antimicrob Agents (2011) 1.00

Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00

Rise and fall of an anti-MUC1 specific antibody. PLoS One (2011) 0.99